MITA Comments on President’s Cancer Moonshot

Feb 4, 2022, 09:38 AM

The initiative will depend on advancing medical imaging innovations.

Washington, D.C – The Medical Imaging & Technology Alliance (MITA) – the leading trade association representing manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices – issued the following statement applauding the Biden Administration's latest effort to reignite the Cancer Moonshot initiative with the new goal of reducing the death rate from cancer by at least 50 percent over the next 25 years while improving the quality of life for patients and their families.  

MITA is encouraged by President and Dr. Biden's commitment to addressing delayed or skipped cancer screenings and health disparities since the two are linked. The effort to encourage Americans to return to care and catch up on cancer screenings missed during the COVID-19 pandemic is also commendable. Regular screenings catch disease when it's most treatable, and the reduction in screenings during the pandemic is a ticking time bomb for too many Americans. That's exactly why MITA has joined provider partners to encourage Americans to return to care. 

As the leading medical imaging and technology trade, MITA stands ready to support and promote efforts to find disease earlier, reduce the cancer death rate, improve everyday lives, and give hope to all those touched by cancer. We look forward to working with the Biden Administration to increase access to cutting-edge diagnostic and therapeutic technologies central to the Administration's goal to "end cancer as we know it." From diagnostics, such as low-dose CT, to non-invasive therapies, such as focused ultrasound, medical imaging technologies are central to reducing cancer deaths. 

We applaud President Biden's commitment to progress and innovation in medical technology to advance and win the fight against cancer.